Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study

被引:10
作者
Koo, Dae-Jeong [1 ]
Lee, Mi Yeon [2 ]
Jung, Inha [3 ]
Moon, Sun Joon [3 ]
Kwon, Hyemi [3 ]
Park, Se Eun [3 ]
Rhee, Eun-Jung [3 ]
Lee, Won-Young [3 ]
机构
[1] Changwon Fatima Hosp, Dept Internal Med, Div Endocrinol & Metab, Chang Won, South Korea
[2] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept R&D Management, Div Biostat,Sch Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Endocrinol & Metab,Sch Med, 29 Saemunan Ro, Seoul 03181, South Korea
关键词
Insulin resistance; Fatty liver; Fibrosis; Body mass index; Cohort studies; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; FOLLOW-UP; HOMA-IR; NAFLD; DIAGNOSIS; PROGRESSION; MECHANISMS; TESTS;
D O I
10.3803/EnM.2021.1110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fibrosis is the most important prognostic factor for nonalcoholic fatty liver disease (NAFLD). Insulin resistance plays a key role of fibrosis progression. We evaluated the association between changes in homeostasis model assessment of insulin resistance (HOMA-IR) values and changes in fibrosis status in NAFLD. Methods: We analyzed the data of 15,728 participants with NAFLD (86% men, mean age 40.5 years) who had no diabetes at baseline and visited our centers for health check-ups both in 2012 and 2016. The participants were classified into four groups according to the degree of change in HOMA-IR values from baseline to the end of follow-up: G1 (<0), G2 (0-0.50), G3 (0.51-1.00), and G4 (>1.00). NAFLD was assessed by ultrasonography, and fibrosis status was evaluated by the NAFLD fibrosis score (NFS) and the aspartate aminotransferase to platelet ratio index (APRI). Results: After the 4-year follow-up, the multivariable-adjusted odds ratio (OR) for progression of fibrosis probability increased with increasing HOMA-IR values (OR, 2.25; 95% confidence interval [CI], 1.87 to 2.71 for NFS; and OR, 2.55; 95% CI, 2.05 to 3.18 for APRI, G4). This tendency remained consistent throughout the subgroup analyses, except in those for female sex and a body mass index <25 kg/m(2). The OR for regression of fibrosis probability decreased with increasing HOMA-IR values (OR, 0.33; 95% CI, 0.25 to 0.43 for NFS, G4). Conclusion: Changes in HOMA-IR values were associated with changes in fibrosis status in patients with NAFLD without diabetes, which underscores the role of insulin resistance in liver fibrosis.
引用
收藏
页码:1016 / 1028
页数:13
相关论文
共 44 条
[1]   Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases [J].
Adams, Leon A. ;
Anstee, Quentin M. ;
Tilg, Herbert ;
Targher, Giovanni .
GUT, 2017, 66 (06) :1138-1153
[2]   Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor [J].
Aller, Rocio ;
Siguenza, Rebeca ;
Pina, Maria ;
Laserna, Cristina ;
Antolin, Beatriz ;
Burgueno, Beatriz ;
Dura, Miguel ;
Izaola, Olatz ;
Primo, David ;
de Luis, Daniel Antonio .
ENDOCRINE, 2020, 68 (03) :557-563
[3]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[4]   Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications [J].
Angulo, Paul ;
Machado, Mariana Verdelho ;
Diehl, Anna Mae .
SEMINARS IN LIVER DISEASE, 2015, 35 (02) :132-145
[5]   Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis [J].
Anstee, Quentin M. ;
Targher, Giovanni ;
Day, Christopher P. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) :330-344
[6]   How can we measure insulin sensitivity/resistance? [J].
Antuna-Puente, B. ;
Disse, E. ;
Rabasa-Lhoret, R. ;
Laville, M. ;
Capeau, J. ;
Bastard, J. -P. .
DIABETES & METABOLISM, 2011, 37 (03) :179-188
[7]   Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms [J].
Bugianesi, E ;
Gastaldelli, A ;
Vanni, E ;
Gambino, R ;
Cassader, M ;
Baldi, S ;
Ponti, V ;
Pagano, G ;
Ferrannini, E ;
Rizzetto, M .
DIABETOLOGIA, 2005, 48 (04) :634-642
[8]   The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Charlton, Michael ;
Cusi, Kenneth ;
Rinella, Mary ;
Harrison, Stephen A. ;
Brunt, Elizabeth M. ;
Sanyal, Arun J. .
HEPATOLOGY, 2018, 67 (01) :328-357
[9]   A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease [J].
Chen, Zhonge ;
Yu, Rong ;
Xiong, Ying ;
Du, Fangteng ;
Zhu, Shuishan .
LIPIDS IN HEALTH AND DISEASE, 2017, 16
[10]   Validity and Reliability of Korean Version of International Physical Activity Questionnaire Short Form in the Elderly [J].
Chun, Min Young .
KOREAN JOURNAL OF FAMILY MEDICINE, 2012, 33 (03) :144-151